Mounjaro Market Size to Hit USD 78.51 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Mounjaro Market

5.1. COVID-19 Landscape: Mounjaro Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Mounjaro Market, By Indication

8.1. Mounjaro Market Revenue and Volume Forecast, by Indication

8.1.1. Type 2 Diabetes

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Obesity / Weight Management

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Prediabetes / Metabolic Syndrome

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Others (e.g., PCOS, cardiovascular protection - off-label use)

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Mounjaro Market, By Route of Administration

9.1. Mounjaro Market Revenue and Volume Forecast, by Route of Administration

9.1.1. Injectable (Subcutaneous Pen)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Oral (Under Development)

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Mounjaro Market, By Dosage Strength

10.1. Mounjaro Market Revenue and Volume Forecast, by Dosage Strength

10.1.1. 2.5 mg

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. 5 mg

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. 7.5 mg

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. 10 mg

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. 12.5 mg

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. 15 mg

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Mounjaro Market, By Distribution Channel

11.1. Mounjaro Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Retail Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Hospital Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Specialty Pharmacies

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Mounjaro Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Indication

12.1.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.3. Market Revenue and Volume Forecast, by Dosage Strength

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Indication

12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.5.3. Market Revenue and Volume Forecast, by Dosage Strength

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Indication

12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.6.3. Market Revenue and Volume Forecast, by Dosage Strength

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Indication

12.2.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.3. Market Revenue and Volume Forecast, by Dosage Strength

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Indication

12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.5.3. Market Revenue and Volume Forecast, by Dosage Strength

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Indication

12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.6.3. Market Revenue and Volume Forecast, by Dosage Strength

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Indication

12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.7.3. Market Revenue and Volume Forecast, by Dosage Strength

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Indication

12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.8.3. Market Revenue and Volume Forecast, by Dosage Strength

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Indication

12.3.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.3. Market Revenue and Volume Forecast, by Dosage Strength

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Indication

12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.5.3. Market Revenue and Volume Forecast, by Dosage Strength

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Indication

12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.6.3. Market Revenue and Volume Forecast, by Dosage Strength

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Indication

12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.7.3. Market Revenue and Volume Forecast, by Dosage Strength

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Indication

12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.8.3. Market Revenue and Volume Forecast, by Dosage Strength

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Indication

12.4.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.3. Market Revenue and Volume Forecast, by Dosage Strength

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Indication

12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.5.3. Market Revenue and Volume Forecast, by Dosage Strength

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Indication

12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.6.3. Market Revenue and Volume Forecast, by Dosage Strength

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Indication

12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.7.3. Market Revenue and Volume Forecast, by Dosage Strength

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Indication

12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.8.3. Market Revenue and Volume Forecast, by Dosage Strength

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Indication

12.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.3. Market Revenue and Volume Forecast, by Dosage Strength

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Indication

12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.5.3. Market Revenue and Volume Forecast, by Dosage Strength

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Indication

12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.6.3. Market Revenue and Volume Forecast, by Dosage Strength

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Pfizer

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerIndicationance

13.1.4. Recent Initiatives

13.2. Boehringer Ingelheim

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerIndicationance

13.2.4. Recent Initiatives

13.3. Johnson & Johnson

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerIndicationance

13.3.4. Recent Initiatives

13.4. Takeda Pharmaceutical

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerIndicationance

13.4.4. Recent Initiatives

13.5. Abbott

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerIndicationance

13.5.4. Recent Initiatives

13.6. Dr. Reddy’s Laboratories

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerIndicationance

13.6.4. Recent Initiatives

13.7. Hanmi Pharmaceutical

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerIndicationance

13.7.4. Recent Initiatives

13.8. LG Chem

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerIndicationance

13.8.4. Recent Initiatives

13.9. Teva Pharmaceutical

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerIndicationance

13.9.4. Recent Initiatives

13.10. Sun Pharma

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerIndicationance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The mounjaro market size is expected to increase from USD 14.18 billion in 2024 to USD 78.51 billion by 2034.

The mounjaro market is expected to grow at a compound annual growth rate (CAGR) of around 18.67%% from 2025 to 2034.

The major players in the mounjaro market include Eli Lilly, Novo Nordisk, Amgen, Pfizer, AstraZeneca, Boehringer Ingelheim, Sanofi, Merck & Co., Johnson & Johnson, Bayer AG, Roche, Takeda Pharmaceutical, Biocon, Innovent Biologics, Dr. Reddy’s Laboratories, Hanmi Pharmaceutical, Zealand Pharma, LG Chem, Cipla, Teva Pharmaceutical, Sun Pharma, and Abvee.

The driving factors of the mounjaro market are the growing demand for effective, long-term weight management solutions further supports market growth

North America region will lead the global mounjaro market during the forecast period 2025 to 2034.